Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVT 101

Small molecule · developed by Evotec Neurosciences GmbH

Phase 1 Most advanced trial (none active)
EVO Developer
1 Registered trials

What is EVT 101?

EVT 101 is an oral capsule formulation tested in single doses of 8 mg and 15 mg.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Developer
Evotec Neurosciences GmbH (EVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
B55T45AA8F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00526968 Phase 1 Human Volunteers Completed EVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Human Volunteers

More from Evotec Neurosciences GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EVO page.

Follow EVO, the company behind EVT 101

See EVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.